-
Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-16 Nada Alsuhebany, Bashayer Alshehri, Atheer Aldairem, Muneerah M. Aleissa, Hajar AlQahtani, Khalid Albarqi, Basil Almotairi, Mohammed AlAmri, Walid Alanazi, Saeed Alay, Bader Alahmari, Mohsen Alzahrani
-
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-16 Emily C. Liang, Kai Rejeski, Teng Fei, Aya Albittar, Jennifer J. Huang, Andrew J. Portuguese, Qian Wu, Sandeep Raj, Marion Subklewe, Roni Shouval, Jordan Gauthier
-
-
Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-16 Jacek Wachowiak, Jacques-Emmanuel Galimard, Arnaud Dalissier, Rawad Rihani, Hawazen AlSaedi, Robert F. Wynn, Jean-Hugues Dalle, Régis Peffault de Latour, Petr Sedlacek, Adriana Balduzzi, Thomas Schroeder, Ivana Bodova, Marta Gonzalez Vicent, Bernd Gruhn, Rose-Marie Hamladji, Gergely Krivan, Katharine Patrick, Agnieszka Sobkowiak-Sobierajska, Polina Stepensky, Ali Unal, Persis Amrolia, Antonio Perez
-
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-13 Yifan Shen, Minyuan Liu, Danya Shen, Mengqian Chu, Xuekai Li, Xiang Zhang, Yi Fan, Jia Chen, Depei Wu, Shaoyan Hu, Yang Xu
-
Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-13 Camila D. Donadel, Gil C. De Santis, Thiago E. Gonçalves, Bruno G. Pires, Leonardo C. Palma, Flavia Gava, Renato Luiz Guerino-Cunha, Joana T. B. Faria, Gabriela V. A. Silva, Luiz Guilherme Darrigo-Junior, Giancarlo Fatobene, Vanderson Rocha, Dimas T. Covas, Rodrigo T. Calado, Diego V. Clé
-
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-13 Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Thomas Schroeder, Rose-Marie Hamladji, Laimonas Griskevicius, Urpu Salmenniemi, Alessandro Rambaldi, Stephan Mielke, Alexander Kulagin, Jakob Passweg, Thomas Luft, Tobias Gedde-Dahl, Edouard Forcade, Grzegorz Helbig, Matthias Stelljes, Cristina Castilla-Llorente, Alexandros Spyridonidis, Eolia Brissot, Fabio Ciceri, Mohamad Mohty
-
Efficacy of eculizumab in transplantation-associated thrombotic microangiopathy: results of the French nationwide study on behalf of the SFGM-TC and the CNR-MAT Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-11 Marion Peyre, Flore Sicre de Fontbrune, Ana Berceanu, Lise Benjemia, Martin Castelle, Maud D’Aveni, Ambroise Marçais, Eleonore Kaphan, Claude-Eric Bulabois, Anne Sirvent, Pierre-Simon Rohrlich, Valerie Coiteux, Sylvain Chantepie, Stéphanie Nguyen-Quoc, Régis Peffault de Latour, Paul Coppo
Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare [1] but severe complication of hematopoietic stem cell transplantation (HSCT), with a letality of 90% without specific treatment. Several triggering factors have been identified (HLA-mismatch, conditioning regimens, immunosuppressive agents, GVHD or viral infections) [2]; recently, the role of uncontrolled complement alternative pathway
-
Insulin eye drops for severe refractory chronic ocular graft-versus-host disease Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-10 V. Tahmaz, L. Menghesha, M. E. Stern, U. Holtick, C. Scheid, P. Steven
-
Post-transplant cyclophosphamide at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-10 Lining Wang, Guilin Xu, Ling Wang, Jieling Jiang, Wenhui Gao, Ming Wan, Didier Blaise, Jiong Hu
-
Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-09 Dimitrios Filioglou, Laurel Truscott, Naresh Reddivalla, Emmanuel Katsanis
Infant leukemia typically refers to the diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) in a child under 1 year of age. Interestingly, the occurrence of AML in infants is nearly equivalent to that of ALL, a contrast from the pattern seen in children older than 1 year in which ALL is five-fold more prevalent. Alterations in the lysine methyltransferase 2A gene (KMT2A)
-
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-05 Xiaoyu Zhang, Xiaoli Zhao, Shulian Chen, Mengze Hao, Lining Zhang, Ming Gong, Yuanyuan Shi, Jialin Wei, Ping Zhang, Sizhou Feng, Yi He, Erlie Jiang, Mingzhe Han
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers rapid hematopoietic and immune reconstitution for aplastic anemia (AA). As a non-malignant disorder, attenuation of GVHD remains a clinical priority in AA patients. Our study sought to investigate the safety and efficacy of the prophylactic use of ruxolitinib in allogeneic HSCT. A total of 35 AA patients were retrospectively consecutively
-
Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-04-02 Rui Ma, Dan-Ping Zhu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Dong Mo, Meng Lv, Yuan-Yuan Zhang, Yi-Fei Cheng, Chen-Hua Yan, Yu-Hong Chen, Yao Chen, Jing-Zhi Wang, Feng-Rong Wang, Ting-Ting Han, Jun Kong, Zhi-Dong Wang, Wei Han, Huan Chen, Ying-Jun Chang, Yun He, Zheng-Li Xu, Feng-Mei Zheng, Hai-Xia Fu, Kai-Yan Liu, Xiao-Jun Huang, Yu-Qian Sun
Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. However, there are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different
-
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-30 Enrico Maffini, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Matthias Stelljes, Thomas Schroeder, Herman Einsele, Johanna Tischer, Martin Bornhäuser, Wolfgang Bethge, Arne Brecht, Wolf Rösler, Peter Dreger, Kerstin Schäfer-Eckart, Jakob Passweg, Igor Wolfgang Blau, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Older adults with acute myeloid leukemia (AML) refractory to initial or reinduction chemotherapy have a dismal prognosis if they do not undergo hematopoietic stem-cell transplantation (HCT). However, data assessing HCT outcomes from different donors are scarce. We evaluated results from a retrospective analysis on patients aged ≥70 years, with AML not in remission who received an allogeneic HCT from
-
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-27 Ray Mun Koo, Eric Wong, Joanne E. Davis, Travis Perera, Andrew Lim, Rachel M. Koldej, David S. Ritchie
-
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-23 Carles Tolosa-Ridao, Enric Cascos, Luis Gerardo Rodríguez-Lobato, Alexandra Pedraza, María Suárez-Lledó, Paola Charry, María Teresa Solano, Julia Martinez-Sanchez, Joan Cid, Miquel Lozano, Laura Rosiñol, Jordi Esteve, Álvaro Urbano-Ispizua, Francesc Fernández-Avilés, Carmen Martínez, Enric Carreras, Maribel Díaz-Ricart, Montserrat Rovira, María Queralt Salas
-
Improving the EASIX’ predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-23 Silvia Escribano-Serrat, Luis Gerardo Rodríguez-Lobato, María Suárez-Lledó, Alexandra Pedraza, Paola Charry, Joan Cid, Miquel Lozano, Jordi Esteve, Laura Rosiñol, Francesc Fernández-Avilés, Enric Carreras, Maribel Díaz-Ricart, Carmen Martínez, Montserrat Rovira, María Queralt Salas
-
-
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-20 Sophie Estran, Michael Loschi, Sami Benachour, Alizée Soldati, Edmond Chiche, Rinzine Sammut, Guillaume Robert, Arnaud Jacquel, Jacques Chibois, Stephane Schneider, Thomas Cluzeau
-
Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-21 Sara Villar, Sylvie Chevret, Xavier Poire, Magalie Joris, Patrice Chevallier, Jean-Henri Bourhis, Edouard Forcade, Sylvain Chantepie, David Beauvais, Nicole Raus, Jacques-Olivier Bay, Michael Loschi, Raynier Devillier, Remy Duléry, Patrice Ceballos, Marie Thérèse Rubio, Sophie Servais, Stephanie Nguyen, Marie Robin
-
Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-19 Romain Guièze, Diderik-Jan Eikema, Linda Koster, Johannes Schetelig, Henrik Sengeloev, Jakob Passweg, Jürgen Finke, Mutlu Arat, Annoek E. C. Broers, Friedrich Stölzel, Jenny Byrne, Cristina Castilla-Llorente, Peter Dreger, Matthias Eder, Tobias Gedde-Dahl, Nicolaus Kröger, Josep Maria Ribera Santasusana, Deborah Richardson, Alessandro Rambaldi, Lucrecia Yañez, Michel Van Gelder, Joanna Drozd-Sokolowska
-
Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-16 Hemang Yadav, Svetlana Herasevich, Zhenmei Zhang, Bradley A. White, Mehrdad Hefazi Torghabeh, William J. Hogan, Philip J. Schulte, Alexander S. Niven, Ognjen Gajic
-
Long term results of a prospective multicenter obervational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study) Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-16 Jürgen Finke, Claudia Schmoor, Francis Ayuk, Justin Hasenkamp, Mareike Verbeek, Eva-Maria Wagner, Harald Biersack, Kerstin Schäfer-Eckart, Dominik Wolf, Gernot Stuhler, Roland Reibke, Christoph Schmid, Martin Kaufmann, Matthias Eder, Hartmut Bertz, Olga Grishina
-
Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-15 Marie Robin, Simona Iacobelli, Linda Koster, Jakob Passweg, Daniele Avenoso, Keith M. O. Wilson, Urpu Salmenniemi, Peter Dreger, Peter von dem Borne, John A. Snowden, Stephen Robinson, Maria Chiara Finazzi, Thomas Schroeder, Matthew Collin, Matthias Eder, Edouard Forcade, Michael Loschi, Stefania Bramanti, Jose Antonio Pérez-Simón, Tomasz Czerw, Nicola Polverelli, Joanna Drozd-Sokolowska, Kavita Raj
-
Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-14 Sabine Fürst, Emmanuelle Bernit, Faezeh Legrand, Angela Granata, Samia Harbi, Raynier Devillier, Valerio Maisano, Benjamin Bouchacourt, Thomas Pagliardini, Djamel Mokart, Claude Lemarié, Boris Calmels, Christophe Picard, Agnès Basire, Borje S. Andersson, Didier Blaise
-
Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-14 Sandra Sauer, Monika Engelhardt, Karolin Trautmann-Grill, Christoph Kimmich, Mathias Hänel, Martin Schmidt-Hieber, Hans Salwender, Carmen Flossmann, Hiltrud Heckmann, Franziska Ertel, Andrea Friederich, Sachin Patel, Barbara Thun, Marc S. Raab
-
Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-12 S. L. Morris, B. R. Thomas, R. Palanicawandar, S. Whittaker, F. Child, M. Wain, V. Sim, R. Szydlo, S. Mangar, E. Olavarria, S. Lozano Cerrada, A. Muzamil, E. Kanfer
-
Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-11 Mohammad Alhomoud, Michael Scordo, Miguel-Angel Perales
-
GVHD like skin eruption post-autologous stem cell transplantation Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-11 Johnathan Fraebel, Silvia Park, Rahul Shah, Carlos Prieto-Granada, Emily F. Mason, Salyka Sengsayadeth, Wichai Chinratanalab, Bipin Savani, Reena V. Jayani, Adetola Kassim, Bhagirathbhai R. Dholaria, Tae Kon Kim
-
Life Blood by David Marks: a review Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-09 Anna Castleton
Professor Marks is a colleague, mentor, and friend. His illustrious and influential career as a haematologist and bone marrow transplanter has resulted in numerous scientific publications, and as such he has firmly established his reputation as an experienced and eloquent scientific writer. When asked to review his book, Life Blood – part semi-fictional work, part real life narrative - I realised that
-
Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-09 Thomas Longval, Anne-Claire Leprêtre, Aurélie Ravinet, Amandine Fayard, Edouard Forcade, Tereza Coman, Rabah Redjoul, Ana Berceanu, Nimrod Buchbinder, Guillaume Berlie, Maria Mappoura, Federica Giannotti, Florian Chevillon, Marie Robin, Régis Peffault de Latour, Flore Sicre de Fontbrune
Pure Red Cell Aplasia (PRCA) after ABO-mismatched Hematopoietic Stem Cell Transplant (HSCT) remains a challenge for physicians. It occurs in 7 to 10% [1,2,3] of major or bi-directional ABO-incompatible HSCT. Although it does not affect overall survival [3, 4], post-transplant PRCA significantly impairs patients’ quality of life due to fatigue, iron-overload and increased risk of transfusion complications
-
Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-08 Guillaume Dachy, Marine Vankeerbergen, Nicolas Vanlangendonck, Nicole Straetmans, Catherine Lambert, Cédric Hermans, Xavier Poiré
Vascular endothelial syndrome is a dreadful post-allogeneic hematopoietic stem cell transplant (alloHSCT) complication, which includes capillary leak syndrome (CLS), engraftment syndrome (ES), transplant-associated thrombotic microangiopathy (TA-TMA), idiopathic pneumonia syndrome (IPS) and diffuse alveolar hemorrhages (DAH) [1, 2]. The development of prognostic scores quantifying comorbidities, disease-
-
-
Late-onset pulmonary complications following allogeneic hematopoietic cell transplantation in pediatric patients: a prospective multicenter study Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-07 Véronique Houdouin, Jean Christophe Dubus, Sophie Guilmin Crepon, Fanny Rialland, Bénedicte Bruno, Charlotte Jubert, Philippe Reix, Marlène Pasquet, Catherine Paillard, Dalila Adjaoud, Cyril Schweitzer, Muriel Le Bourgeois, Justine Pages, Adyla Yacoubi, Jean Hugues Dalle, Anne Bergeron, Christophe Delclaux
-
Long-term follow-up of cancer and catastrophic diseases in hematopoietic stem cell donors: a comprehensive matched cohort study Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-07 Sung-Chao Chu, Chia-Jung Hsieh, Chi-Cheng Li, Shang-Hsien Yang, Szu-Chin Li, Woei-Yau Kao, Dian-Kun Li, Yi-Feng Wu, Ruey-Ho Kao, Kuo‐Liang Yang, Tso-Fu Wang
-
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-05 Anna Sureda, Paul A. Carpenter, Andrea Bacigalupo, Vijaya Raj Bhatt, Josu de la Fuente, Aloysius Ho, Leslie Kean, Jong Wook Lee, Isabel Sánchez-Ortega, Bipin N. Savani, Johannes Schetelig, Edward A. Stadtmauer, Yoshiyuki Takahashi, Yoshiko Atsuta, John Koreth, Nicolaus Kröger, Per Ljungman, Shinichiro Okamoto, Uday Popat, Robert Soiffer, Heather E. Stefanski, Mohamed A. Kharfan-Dabaja
-
Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-05 Qianwen Shang, Lu Bai, Yifei Cheng, Pan Suo, Guanhua Hu, Chenhua Yan, Yu Wang, Xiaohui Zhang, Lanping Xu, Kaiyan Liu, Xiaojun Huang
-
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1 Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-04 Silvia Park, Su-Yeon Bang, Daehun Kwag, Jong Hyuk Lee, Tong Yoon Kim, Joonyeop Lee, Gi June Min, Sung Soo Park, Seung-Ah Yahng, Young-Woo Jeon, Seung-Hwan Shin, Jae-Ho Yoon, Sung-Eun Lee, Byung Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Hee-Je Kim
-
Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-05 L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel
-
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-04 Jakob R. Passweg, Helen Baldomero, Fabio Ciceri, Rafael de la Cámara, Bertram Glass, Raffaella Greco, Mette D. Hazenberg, Krzysztof Kalwak, Donal P. McLornan, Bénédicte Neven, Zinaida Perić, Antonio M. Risitano, Annalisa Ruggeri, John A. Snowden, Anna Sureda
-
Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-03-02 Kentaro Fukushima, Hayami Kudo, Kentaro Oka, Atsushi Hayashi, Makoto Onizuka, Shinsuke Kusakabe, Akihisa Hino, Motomichi Takahashi, Kiyoshi Takeda, Masaki Mori, Kiyoshi Ando, Naoki Hosen
-
Prevalence of osteoporosis among patients after stem cell transplantation: a systematic review and meta-analysis Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-29 Yu-Mei Yang, Shu-Jin Guo, Rong Xiao, Xi-Jie Yu, Yu-Ping Liu, Ping Shuai
-
How to decrease bone marrow collection volume and risk contaminations via the operating room cell concentration? Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-28 Yoann Grimaud, Flore Sicre de Fontbrune, David Michonneau, Aude Desnoyer, Régis Peffault de Latour, Jérôme Larghero, Justine Nasone, Lionel Faivre
-
Early lymphocyte reconstitution and viral infections in adolescents and adults transplanted for sickle cell disease Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-27 Loïc Vasseur, Alexis Cuffel, Corinne Pondarré, Jean-Hugues Dalle, Florian Chevillon, Aude-Marie Fourmont, Edouard Flamarion, Karima Yakouben, Valérie Guérin-El Khourouj, Florence Morin, Clara Ibanez, Régis Peffault de Latour, Nicolas Boissel, Jean-Benoit Arlet, Hélène Moins-Teisserenc, Sophie Caillat-Zucman, Nathalie Dhédin
Allogeneic hematopoietic stem cell transplantation is a curative therapy for sickle cell disease (SCD). Most reports concern myeloablative (MAC) matched related transplants (MRT) performed in children. Older age is associated with increased toxicity of transplants, resulting in new approaches with reduced intensity conditioning (RIC) regimens for adults. A non-myeloablative (NMA) conditioning regimen
-
International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-27 Seth J. Rotz, Neel S. Bhatt, Betty K. Hamilton, Christine Duncan, Mahmoud Aljurf, Yoshiko Atsuta, Kristen Beebe, David Buchbinder, Peggy Burkhard, Paul A. Carpenter, Naeem Chaudhri, Mohamed Elemary, Mahmoud Elsawy, Gregory M. T. Guilcher, Nada Hamad, Amado Karduss, Zinaida Peric, Duncan Purtill, Douglas Rizzo, Morgani Rodrigues, Maria Belén Rosales Ostriz, Nina Salooja, Helene Schoemans, Adriana Seber
-
Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-26 María E. Martínez-Muñoz, Concepción Payares-Herrera, Inés Lipperheide, Rosa Malo de Molina, Isabel Salcedo, Rosalía Alonso, Trinidad Martín-Donaire, Rocío Sánchez, Rocío Zafra, Miguel García-Berciano, Andrea Trisán-Alonso, Manuel Pérez-Torres, Antonio Ramos-Martínez, Piedad Ussetti, Juan J. Rubio, Cristina Avendaño-Solà, Rafael F. Duarte
-
Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-24 Maria Chiara Finazzi, Alessandra Weber, Chiara Pavoni, Anna Grassi, Maria Caterina Micò, Alessandra Algarotti, Federico Lussana, Alessandro Rambaldi
-
Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-24 Francesco Baccelli, Francesca Gottardi, Edoardo Muratore, Davide Leardini, Antonio Giacomo Grasso, Davide Gori, Tamara Belotti, Arcangelo Prete, Riccardo Masetti
-
Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-24 Alistair Murray, Swe Mar Linn, Benoit Yu, Igor Novitzky-Basso, Jonas Mattsson, Michael Kennah, Mohamed Elemary, Jennifer White, Christopher Lemieux, Kareem Jamani, Dennis Dong Hwan Kim
-
Remuneration of donors for cell and gene therapies: an update on the principles and perspective of the World Marrow Donor Association Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-23 Lina Hamad, Salmah Mahmood Ahmed, Eefke van Eerden, Suzanna M. van Walraven, Laura Machin
-
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-21 Hoi Ki Karen Tang, Chi Yeung Fung, Yu Yan Hwang, Harold Lee, Grace Lau, Sze Fai Yip, Bonnie Kho, Chi Kuen Lau, Kwan Hung Leung, Elaine Au, Eric Tse, Joycelyn Sim, Yok Lam Kwong, Chor Sang Chim
-
Return to school practices after hematopoietic cell transplantation: a survey of transplant centers in the United States Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-20 Neel S. Bhatt, Christa L. Meyer, Lih-Wen Mau, Jeffery J. Auletta, K. Scott Baker, Larisa Broglie, Paul A. Carpenter, Sung Won Choi, Christopher E. Dandoy, Steven Devine, Rachel Phelan
-
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-21 Dietrich Wilhelm Beelen, Simona Iacobelli, Linda Koster, Dirk-Jan Eikema, Anja van Biezen, Friedrich Stölzel, Fabio Ciceri, Wolfgang Bethge, Peter Dreger, Eva-Maria Wagner-Drouet, Péter Reményi, Matthias Stelljes, Miroslaw Markiewicz, Donal P. McLornan, Ibrahim Yakoub-Agha, Mohamad Mohty
-
Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-21 Lev Gorfinkel, Sharmila Raghunandan, Benjamin Watkins, Kyle Hebert, Donna S. Neuberg, Brandi Bratrude, Kayla Betz, Alison Yu, Sung W. Choi, Jeffrey Davis, Christine Duncan, Roger Giller, Michael Grimley, Andrew C. Harris, David Jacobsohn, Nahal Lalefar, Nosha Farhadfar, Michael A. Pulsipher, Shalini Shenoy, Aleksandra Petrovic, Kirk R. Schultz, Gregory A. Yanik, Bruce R. Blazar, John T. Horan, Amelia
-
Comparison of haploidentical transplantation and single cord blood transplantation for myelofibrosis Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-20 Kazuki Sakatoku, Makoto Murata, Yutaka Shimazu, Naoyuki Uchida, Satoshi Yoshihara, Yasufumi Uehara, Satoshi Takahashi, Hikaru Kobayashi, Haruyuki Tanaka, Nobuaki Nakano, Fumihiko Ishimaru, Tatsuo Ichinohe, Yoshiko Atsuta, Tokiko Nagamura-Inoue, Hirohisa Nakamae
-
Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-14 Simona Piemontese, Maria Teresa Lupo Stanghellini, Federica Sora, Simona Sica, Jacopo Peccatori, Magda Marcatti, Elisabetta Metafuni, Sabrina Giammarco, Raffaella Greco, Alessandro Bruno, Fabio Ciceri, Andrea Bacigalupo, Patrizia Chiusolo
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative option for patients with hematological malignancies but graft-versus-host disease (GvHD) is still a major cause of morbidity and mortality even in the setting of HLA-matched donors [1]. The ideal GvHD prophylaxis to choose remains to be identified. The most widely used strategy for GvHD prevention, at least in Europe
-
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-15 Meera Mohan, Aniko Szabo, Anannya Patwari, Jean Esselmann, Tanvi Patel, Ramya Bachu, Lisa E. Rein, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Catherine Skoog, Areyl Goff, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Sharmilan Thanendrarajan, Maurizio Zangari, Nirav Shah, Frits van Rhee, Binod Dhakal, Mehdi Hamadani, Anita D’Souza, Carolina Schinke
-
Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-15 Thirupathi Pattipaka, Séverine Sarp, Peyman Nakhaei, Sibel Güneş
-
-
Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation Bone Marrow Transpl. (IF 4.8) Pub Date : 2024-02-13 Giovanna Melica, Elaina Preston, Meighan Palazzo, Kenneth Seier, Florent Malard, Christina Cho, Sean M. Devlin, Molly Maloy, Taylor Borrill, Peter Maslak, Gunjan L. Shah, Miguel-Angel Perales
Myeloablative T cell depleted (CD34-selected) hematopoietic cell transplantation (HCT) is associated with less acute and chronic graft versus host disease (GVHD). We aimed to examine vaccine responses in relation to immune reconstitution and post HCT rituximab administration in this population. This single center retrospective study included 251 patients with hematological malignancies who received